CA2491210A1 - Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis - Google Patents

Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis Download PDF

Info

Publication number
CA2491210A1
CA2491210A1 CA002491210A CA2491210A CA2491210A1 CA 2491210 A1 CA2491210 A1 CA 2491210A1 CA 002491210 A CA002491210 A CA 002491210A CA 2491210 A CA2491210 A CA 2491210A CA 2491210 A1 CA2491210 A1 CA 2491210A1
Authority
CA
Canada
Prior art keywords
formula
compound
group
alkyl
cndot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491210A
Other languages
English (en)
French (fr)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2491210A1 publication Critical patent/CA2491210A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/241,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26Two oxygen atoms, e.g. isatoic anhydride
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/041,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/081,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002491210A 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis Abandoned CA2491210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
EPPCT/EP/02/08062 2002-06-25
PCT/EP2003/006601 WO2004000322A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Publications (1)

Publication Number Publication Date
CA2491210A1 true CA2491210A1 (en) 2003-12-31

Family

ID=29797117

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491210A Abandoned CA2491210A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Country Status (6)

Country Link
JP (1) JP2005538965A (ja)
AU (2) AU2002333256A1 (ja)
BR (1) BR0312107A (ja)
CA (1) CA2491210A1 (ja)
MX (1) MXPA05000004A (ja)
WO (2) WO2004000321A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
JP2006504665A (ja) 2002-08-13 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001783A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
CN112159347B (zh) * 2020-10-27 2022-06-07 常州工程职业技术学院 吡考他胺的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037454B2 (ja) * 1976-12-17 1985-08-26 富士写真フイルム株式会社 熱現像感光材料

Also Published As

Publication number Publication date
MXPA05000004A (es) 2005-04-08
AU2002333256A1 (en) 2004-01-06
JP2005538965A (ja) 2005-12-22
WO2004000321A1 (en) 2003-12-31
WO2004000322A1 (en) 2003-12-31
BR0312107A (pt) 2005-03-29
AU2003246574A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
US20040006077A1 (en) Thiazine and oxazine derivatives as MMP-13 inhibitors
EP0471236B1 (en) Imidazopyridine derivatives and their use
US20030216402A1 (en) Oxo-azabicyclic compounds
US6747147B2 (en) Oxo-azabicyclic compounds
KR100421156B1 (ko) 단백질티로신키나제매개세포증식을억제하기위한피리도[2,3-d]피리미딘
US6962922B2 (en) Alkynylated quinazoline compounds
AU673103B2 (en) Aryl and heterocyclic cyanoguanidine derivatives
CA2478706A1 (en) Oxo-azabicyclic compounds
CA2437588A1 (en) Triazolo compounds as mmp inhibitors
US20050245548A1 (en) Alkynylated fused ring pyrimidine compounds
CA2491210A1 (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
HUT60462A (en) Process for producing biphenyl derivatives and pharmaceutical compositions comprising same
PL194735B1 (pl) Pochodne benzosulfonowe, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
CA3063111A1 (en) Histone deacetylases (hdacs) inhibitors
WO2010032010A1 (en) Aryl-phenyl-sulfonamide-phenylene compounds and their use
JPH10510536A (ja) 2−置換された1,2,5−チアジアゾリジン−3−オン1,1−ジオキシド及びそれらの組成物
NZ233252A (en) Thiourea and guanidine derivatives and pharmaceutical compositions
NZ232008A (en) Condensed quinoline system compound and process of preparation thereof
AU767923B2 (en) Novel 2-(N-cyanoimino)thiazolidin-4-one derivatives
NZ573479A (en) Matrix metalloproteinase inhibitors
PL154813B1 (en) Method of obtaining s enantiomeric derivatives of glutar amide
FI91257C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-okso-4H-pyrido/1,2-a/pyrimidiini-3-karboksamidijohdannaisten valmistamiseksi
EP1539176A1 (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
WO2003033477A1 (en) Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US5856337A (en) 2-arylquinolines and process for producing the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead